循环游离DNA突变在未分化甲状腺癌中的临床价值
本研究纳入2015年1月至2018年2月在MD Anderson癌症中心诊治且接受cfDNA检测的87例未分化甲状腺癌(ATC)患者,采用Guardant360-73基因平台NGS分析cfDNA。在28例初治患者中,cfDNA与配对组织NGS检测TP53、BRAFV600E、PIK3CA突变的一致率分别为82.1%、92.9%、92.9%;cfDNA检出PIK3CA突变者总生存更差(p=0.03),BRAF抑制剂治疗显著改善OS(p=0.003)。
要点
- cfDNA与肿瘤组织NGS检测ATC相关突变一致率高,可快速反映分子分型。
- cfDNA检出PIK3CA突变与更差的总生存相关(p=0.03)。
- BRAF抑制剂治疗显著改善ATC患者总生存(p=0.003)。
核心结论
- cfDNA是评估ATC肿瘤分子谱的有价值工具,其检测突变与组织NGS高度一致。
- cfDNA突变可及时指导治疗选择并评估预后。
研究设计与样本
- 回顾性纳入2015年1月至2018年2月MD Anderson癌症中心诊治且接受cfDNA检测的87例ATC患者。
- cfDNA通过抽血采集,采用Guardant360-73基因平台NGS分析。
- 在28例初治ATC患者中比较cfDNA与配对肿瘤组织NGS的突变一致性。
主要发现
- cfDNA中最常见突变基因为TP53、BRAF和PIK3CA。
- 28例初治患者中,cfDNA与组织NGS检测TP53、BRAFV600E、PIK3CA突变的一致率分别为82.1%、92.9%、92.9%。
- cfDNA检出PIK3CA突变者总生存更差(p=0.03),该关联在手术、细胞毒化疗、放疗和BRAF抑制剂治疗中均观察到。
- BRAF抑制剂治疗显著改善ATC患者总生存(p=0.003)。
临床怎么用
- 对ATC患者可行cfDNA NGS检测以快速获取肿瘤分子谱,辅助早期诊断和治疗选择。
- cfDNA检出PIK3CA突变提示预后较差,可考虑加强监测和个体化治疗。
- BRAF抑制剂治疗可显著改善ATC患者总生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Anaplastic thyroid carcinoma (ATC) is an aggressive thyroid cancer that requires a rapid diagnosis and treatment to achieve disease control. Gene mutation profiling of circulating cell-free DNA (cfDNA) in peripheral blood may help to facilitate early diagnosis and treatment selection. The relatively rapid turnaround time compared with conventional tumor mutation testing is a major advantage. The objectives of this study were to examine the concordance of ATC-related mutations detected in cfDNA with those detected in the corresponding tumor tissue, and to determine the prognostic significance of cfDNA mutations in ATC patients. Methods: The ATC patients who were diagnosed and treated at The University of Texas MD Anderson Cancer Center between January 2015 and February 2018 and who had cfDNA testing were included in this study. cfDNA was collected by blood draw and was analyzed by next-generation sequencing (NGS) using the Guardant360-73 gene platform. Results: A total of 87 patients were included in the study. The most frequently mutated genes detected in cfDNA were TP53, BRAF, and PIK3CA. In 28 treatment naive ATC patients, the concordance rate of detected mutations in TP53, BRAFV600E, and PIK3CA between cfDNA and matched tissue NGS was 82.1%, 92.9%, and 92.9%, respectively. Patients with a PIK3CA mutation detected on cfDNA had worse overall survival (OS) (p = 0.03). This association was observed across various treatment modalities, including surgery, cytotoxic chemotherapy, radiation, and BRAF inhibitor (BRAFi) therapy. With regard to treatment, BRAFi therapy significantly improved ATC OS (p = 0.003). Conclusions: cfDNA is a valuable tool to evaluate a tumor's molecular profile in ATC patients. We identified high concordance rates between the gene mutations identified via cfDNA analysis and those identified from the NGS of the corresponding tumor tissue sequencing. Identified mutations in cfDNA can potentially provide timely information to guide treatment selection and evaluate the prognosis in patients with ATC.
引用
- Qin Y, Wang JR, Wang Y, et al. Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma. Thyroid. 2021. PMID: 33599171. doi:10.1089/thy.2020.0296
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。